Home Newsfeeds Wolfe Research Initiates Coverage On Matson with Underperform Rating, Announces Price Target of $80

Wolfe Research Initiates Coverage On Matson with Underperform Rating, Announces Price Target of $80

Wolfe Research analyst Jacob Laclks initiates coverage on Matson (NYSE:MATX) with a Underperform rating and announces Price Target of $80.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Wolfe Research analyst Jacob Laclks initiates coverage on Matson (NYSE:MATX) with a Underperform rating and announces Price Target of $80.

Apollo Backs Wolfspeed with $2B for Expansion, Boosting US Silicon Carbide Supply

By Anusuya Lahiri

June 26, 7:34 AM

A group of lenders led by Apollo Global Management Inc (NYSE: APO) provides up to $2 billion to Wolfspeed Inc (NYSE: WOLF) to support the latter's

APO

“EDF Energy Aims To Extend Life Of UK Nuclear Plants; The French State-Owned Firm Said It Would Make A Decision On Whether To Extend The Lives Of Four UK Plants By The End Of The Year” – BBC

By Benzinga Newsdesk

January 9, 12:30 PM

https://www.bbc.com/news/business-67924012EDF Energy has outlined plans to extend the lives of its operational nuclear power stations in the UK.The French state-owned firm said it would make a decision on whether to

CCJ

Insiders Buying Synchronoss Technologies And 2 Other Stocks

By Avi Kapoor

January 5, 9:38 AM

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

HQH

Investigator-Initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat In Combination With Azacitidine To Treat Hematologic Cancers Resumes Patient Enrollment

By Benzinga Newsdesk

January 3, 9:44 AM

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center (MDACC or MD Anderson) is now listed as

SLRX

Wolfe Research Initiates Coverage On Matson with Underperform Rating, Announces Price Target of $80

Related Posts

Apollo Backs Wolfspeed with $2B for Expansion, Boosting US Silicon Carbide Supply

“EDF Energy Aims To Extend Life Of UK Nuclear Plants; The French State-Owned Firm Said It Would Make A Decision On Whether To Extend The Lives Of Four UK Plants By The End Of The Year” – BBC

Insiders Buying Synchronoss Technologies And 2 Other Stocks

Investigator-Initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat In Combination With Azacitidine To Treat Hematologic Cancers Resumes Patient Enrollment